Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Answer: Can you identify this condition?

Vimal Prajapati and P. Régine Mydlarski
Canadian Family Physician November 2008; 54 (11) 1558;
Vimal Prajapati
First-year dermatology resident at the University of Alberta in Edmonton
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Régine Mydlarski
Assistant Professor in the departments of medicine and medical genetics at the University of Calgary in Alberta
MD FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading
Figure

Answer to Dermacase continued from page 1557

4. Tinea versicolor

Tinea versicolor, also known as pityriasis versicolor, is a common superficial fungal infection of the skin caused by yeast species of the Malassezia genus. It affects nearly 1% of the general population and has an incidence of up to 50% in some tropical climates.1 In temperate climates, eruptions occur more commonly in the summer than in the winter months.1 The disease primarily affects adolescents and young adults, although it can occur at any age.

Clinically, tinea versicolor presents as multiple well-demarcated, scaly, oval-to-round hypo- or hyperpigmented macules that frequently coalesce into larger patches. The scale on the patches is usually subtle and is often best visualized by gently scraping the skin with a scalpel blade, the edge of a glass slide, or a fingernail.2 As the term versicolor implies, the lesions can be of varying colours, such as white, pink, tan, light brown, and dark brown.2,3 The lesions are typically distributed on the upper trunk, upper arms, and neck.4 A follicular variant and an inverse form that involves the face, flexural regions, and extremities, have also been described.4 Although the disease is generally asymptomatic, patients might complain of pruritus.

Tinea versicolor is caused by dimorphic, lipophilic Malassezia organisms (Malassezia furfur being the most common), which are part of the normal skin flora. Clinical disease occurs when these organisms convert from their saprophytic yeast form to their pathogenic mycelial or hyphal form.4 This conversion can be triggered by a variety of exogenous and endogenous factors, including heat and moisture, occlusion of the skin by clothing or cosmetics, use of body oils, use of systemic corticosteroids, immunosuppression, Cushing disease, malnutrition, pregnancy, and hyperhidrosis. Hereditary factors might also play a role.2

The underlying mechanisms of hypo- and hyperpigmentation in tinea versicolor are not fully understood. Hypopigmentation might result from yeast production of azelaic acid, which inhibits tyrosinase, an enzyme responsible for melanin synthesis. Another possible explanation suggests that the thickened epidermis and scale characteristic of tinea versicolor blocks ultraviolet light and prevents tanning. Hyperpigmentation might result from a pronounced inflammatory response to the infection.2

Diagnosis

Diagnosis of tinea versicolor is made clinically and is confirmed by direct microscopic examination of scale prepared with 10% potassium hydroxide solution. The presence of both hyphae and spores in the characteristic “spaghetti and meatballs” pattern is diagnostic. A Wood lamp examination can also be useful, as affected areas might fluoresce a bright yellow to coppery orange colour. This finding, however, only occurs in around one-third of cases.5 Skin biopsy and culture are not generally required to confirm diagnosis.

The differential diagnoses for tinea versicolor include vitiligo, pityriasis alba, postinflammatory hypo- and hyperpigmentation, seborrheic dermatitis, pityriasis rosea, guttate psoriasis, tinea corporis, nummular eczema, secondary syphilis, confluent reticulated papillomatosis of Gougerot and Carteaud, and mycosis fungoides.

Treatment

Tinea versicolor responds well to a variety of topical and systemic treatments. Topical therapy is generally reserved for patients with limited skin disease whereas systemic therapy is preferred for patients with more extensive or recurrent disease.

Topical treatment options include both nonspecific and specific antifungal agents. Nonspecific agents act by physically or chemically removing the infected stratum corneum without having direct antifungal activity.5 Examples include selenium sulfide, propylene glycol, benzoyl peroxide, and sulfur with salicylic acid. The most commonly used is 2.5% selenium sulfide. Available as a lotion, cream, or shampoo, it is applied to affected areas for 10 to 15 minutes daily, then washed off. The typical course of therapy is 7 days. Although it is effective, patients might complain about its unpleasant odour and a stinging sensation after application.6

Topical antifungal agents include the azoles and allylamines. A number of topical azoles have demonstrated efficacy in treating tinea versicolor, including ketoconazole, fluconazole, clotrimazole, miconazole, econazole, sertaconazole, and flutrimazole.1,5,7 Ketoconazole is the agent most commonly used. It is available as a cream or shampoo. Ketoconazole 2% shampoo has been shown to be effective when applied daily for 1, 3, or 14 days.7,8 Terbinafine, an allylamine that is offered as a 1% cream or spray, has also been successful when applied twice daily for 7 days.5

Systemic therapy involves the use of oral antifungal agents. Ketoconazole is used most widely, although other options include fluconazole and itraconazole. Therapeutic efficacy with ketoconazole has been demonstrated at a daily dose of 200 mg for 5, 10, 14, or 28 days; and at a dose of 400 mg when administered once daily for 3 days, once weekly for 2 weeks, or 3 times every 12 hours or 7 days.5 A single 400-mg dose can also be effective, although relapse rates are thought to be higher with this regimen.9 The typical regimen for itraconazole is 200 mg/d for either 5 or 7 days, and fluconazole is given at a dose of 150 to 300 mg once weekly for 2 or 4 weeks. Many azoles are excreted by the eccrine sweat glands, so exercise and sweating after ingesting the oral medication might increase efficacy. Oral terbinafine and griseofulvin are generally ineffective in treating tinea versicolor.5

While a mycological cure can be achieved, normal pigmentation of the affected areas might not return for months after treatment cessation. Patients should be advised to avoid prolonged sun exposure during this time, as tanning will enhance the contrast between affected areas and normal skin.

Recurrence of tinea versicolor is not uncommon. For patients with frequent relapses, prophylactic treatment might be required. Effective options include monthly treatments of oral ketoconazole (a single 400-mg dose or 200 mg/d for 3 days) and itraconazole (a single 400-mg dose).5

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Gupta AK,
    2. Bluhm R,
    3. Summerbell R
    . Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002;16(1):19-33.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Sunenshine PJ,
    2. Schwartz RA,
    3. Janniger CK
    . Tinea versicolor. Int J Dermatol 1998;37(9):648-55.
    OpenUrlPubMed
  3. ↵
    1. Gupta AK,
    2. Batra R,
    3. Bluhm R,
    4. Boekhout T,
    5. Dawson TL Jr
    . Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004;51(5):785-98.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Gupta AK,
    2. Ryder JE,
    3. Nicol K,
    4. Cooper EA
    . Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol 2003;21(5):417-25.
    OpenUrlPubMed
  5. ↵
    1. Gupta AK,
    2. Batra R,
    3. Bluhm R,
    4. Faergemann J
    . Pityriasis versicolor. Dermatol Clin 2003;21(3):413-29.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Faergemann J
    . Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1(2):75-80.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Rigopoulos D,
    2. Gregoriou S,
    3. Kontochristopoulos G,
    4. Ifantides A,
    5. Katsambas A
    . Flutrimazole shampoo 1% versus ketoconazole shampoo 2% in the treatment of pityriasis versicolor. A randomised double-blind comparative trial. Mycoses 2007;50(3):193-5.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lange DS,
    2. Richards HM,
    3. Guarnieri J,
    4. Humeniuk JM,
    5. Savin RC,
    6. Reyes BA,
    7. et al
    . Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 1998;39(6):944-50.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Sadeque JB,
    2. Shahidullah M,
    3. Shah OR,
    4. Kamal M
    . Systemic ketoconazole in the treatment of tinea versicolor. Int J Dermatol 1995;34(7):504-5.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 54 (11)
Canadian Family Physician
Vol. 54, Issue 11
1 Nov 2008
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Answer: Can you identify this condition?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Answer: Can you identify this condition?
Vimal Prajapati, P. Régine Mydlarski
Canadian Family Physician Nov 2008, 54 (11) 1558;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Answer: Can you identify this condition?
Vimal Prajapati, P. Régine Mydlarski
Canadian Family Physician Nov 2008, 54 (11) 1558;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • 4. Tinea versicolor
    • Diagnosis
    • Treatment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Question: Can you identify this condition?
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
Show more Practice

Dermacase

  • Question: Can you identify this condition?
  • Answer: Can you identify this condition?
  • Question: Can you identify this condition?
Show more Dermacase

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire